期刊
BRAIN RESEARCH
卷 891, 期 1-2, 页码 42-53出版社
ELSEVIER SCIENCE BV
DOI: 10.1016/S0006-8993(00)03186-3
关键词
Alzheimer's disease; transgenic mice; amyloid precursor protein; presenilin-1; cognitive performance; sensorimotor function
资金
- NIA NIH HHS [AG15490, AG14633] Funding Source: Medline
This study provides a comprehensive behavioral characterization during aging of transgenic mice bearing,a both presenilin-1 (PS1) and amyloid precursor protein (APP(670,671)) mutations. Doubly transgenic mice and non-transgenic controls were evaluated at ages wherein beta -amyloid (A beta) neuropathology in APP+PS1 mice is low (5-7 months) or very extensive (15-17 months). Progressive cognitive impairment was observed in transgenic mice for both water maze acquisition and radial arm water maze working memory. However, transgenicity did not affect Y-maze alternations, circular platform performance, standard water maze retention, or visible platform recognition at either age, nor did transgenicity affect anxiety levels in elevated plus-maze testing. In sensorimotor tasks, transgenic mice showed a progressive increase in open field activity, a progressive impairment in string agility, and an early-onset impairment in balance: beam. None of these sensorimotor changes appeared to be contributory to any cognitive impairments observed, however. Non-transgenic mice showed no progressive behavioral change in any measure evaluated. Given the age-related cognitive impairments presently observed in APP+PS1 transgenic mice and their progressive A beta deposition/neuroinflammation, A beta neuropathology could be involved in these progressive cognitive impairments. As such, the APP+PS1 transgenic mouse offers unique opportunities to develop therapeutics to treat or prevent Alzheimer's Disease through modulation of A beta deposition/neuroinflammation. (C) 2001 Elsevier Science B.V. All rights reserved.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据